Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Autologous Transplantation After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma - a Randomized European Mcl Network Trial

NCT02858258 is registered in ClinicalTrials.gov with Prof. Dr. M. Dreyling (co-chairman) as lead sponsor.

NCT NCT02858258
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02858258 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Autologous Transplantation After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma - a Randomized European Mcl Network Trial
Lead sponsor
Prof. Dr. M. Dreyling (co-chairman)
Phase
Phase 3
Overall status
Unknown status
Start date
July 31, 2016
Completion date
May 31, 2026
Enrollment
870 (estimated)
Sites
112

Conditions

As the registry lists them; a condition with its own page is linked.

mantle cell lymphoma